quizartinib | FDA approves quizartinib for newly diagnosed acute myelo

Keyword	CPC	PCC	Volume	Score	Length of keyword
quizartinib	1.44	0.5	8465	54	11

Keyword	CPC	PCC	Volume	Score
quizartinib	1	0.9	1243	19

Search Results related to quizartinib on Search Engine

FDA approves quizartinib for newly diagnosed acute myeloid …
fda.gov

https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-quizartinib-newly-diagnosed-acute-myeloid-leukemia

WEBOn July 20, 2023, the Food and Drug Administration approved quizartinib (Vanflyta, Daiichi Sankyo, Inc.) with standard cytarabine and anthracycline induction and cytarabine consolidation, and as...

DA: 55 PA: 56 MOZ Rank: 50

Quizartinib - Wikipedia
wikipedia.org

https://en.wikipedia.org/wiki/Quizartinib

WEBQuizartinib, sold under the brand name Vanflyta, is an anti-cancer medication used for the treatment of acute myeloid leukemia. It is a small molecule receptor tyrosine kinase inhibitor. Its molecular target is FLT3, also known as CD135 which is a proto-oncogene.

DA: 73 PA: 15 MOZ Rank: 37

Quizartinib plus chemotherapy in newly diagnosed patients with
thelancet.com

https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(23)00464-6/fulltext

WEBQuizartinib, an oral, highly potent, selective, type 2 FLT3 inhibitor, plus chemotherapy showed antitumour activity with an acceptable safety profile in patients with FLT3-ITD-positive newly diagnosed AML.

DA: 92 PA: 87 MOZ Rank: 77

FDA Approves Vanflyta for FLT3-Mutated AML - NCI
cancer.gov

https://www.cancer.gov/news-events/cancer-currents-blog/2023/fda-vanflyta-aml-flt3

WEBAug 15, 2023 · Quizartinib Approval Adds New Treatment Option for AML, Including in Older Patients. Subscribe. August 15, 2023 , by Carmen Phillips. Quizartinib specifically targets FLT3 proteins with ITD mutations, while similar drugs like midostaurin and gilteritinib target FLT3 proteins with both ITD and TKD mutations.

DA: 40 PA: 56 MOZ Rank: 15

Quizartinib Uses, Side Effects & Warnings - Drugs.com
drugs.com

https://www.drugs.com/mtm/quizartinib.html

WEBNov 28, 2023 · Drug class: Multikinase inhibitors. Medically reviewed by Drugs.com on Nov 28, 2023. Written by Cerner Multum. Uses. Side effects. Warnings. Before taking. Dosage. Interactions. What is quizartinib? Quizartinib is used in adults alone or in combination with other cancer treatments to treat acute myeloid leukemia.

DA: 23 PA: 12 MOZ Rank: 79

Quizartinib Dihydrochloride - NCI - National Cancer Institute
cancer.gov

https://www.cancer.gov/about-cancer/treatment/drugs/quizartinib-dihydrochloride

WEBQuizartinib dihydrochloride is approved to treat: Acute myeloid leukemia that is newly diagnosed and has a certain mutation in the FLT3 gene. It is used in adults, first with cytarabine and an anthracycline drug as induction therapy, next with cytarabine as consolidation therapy, and then alone as maintenance therapy.

DA: 64 PA: 82 MOZ Rank: 53

Newly diagnosed AML: quizartinib improves OS - Nature
nature.com

https://www.nature.com/articles/s41571-023-00787-6

WEBMay 30, 2023 · Newly diagnosed AML: quizartinib improves OS. David Killock. Nature Reviews Clinical Oncology 20 , 504 ( 2023) Cite this article. 542 Accesses. 1 Citations. 4 Altmetric. Metrics. FLT3 internal...

DA: 71 PA: 64 MOZ Rank: 50

Quizartinib Granted Priority Review in the U.S. for Patients with …
daiichisankyo.us

https://daiichisankyo.us/press-releases/-/article/quizartinib-granted-priority-review-in-the-u-s-for-patients-with-newly-diagnosed-flt3-itd-positive-acute-myeloid-leukemia

WEBOct 24, 2022 · Quizartinib Granted Priority Review in the U.S. for Patients with Newly Diagnosed FLT3-ITD Positive Acute Myeloid Leukemia. Download the PDF version of Article. October 24, 2022. Submission based on QuANTUM-First results showing quizartinib plus chemotherapy significantly improved overall survival compared to …

DA: 36 PA: 34 MOZ Rank: 21

Vanflyta | European Medicines Agency
europa.eu

https://www.ema.europa.eu/en/medicines/human/EPAR/vanflyta-0

WEBquizartinib. Medicine Human. Overview. Vanflyta is a cancer medicine used to treat adults who have been newly diagnosed with acute myeloid leukaemia (AML), a cancer of the white blood cells. It is only given to those patients whose cancer cells have a particular change (mutation) known as ITD in the gene for a protein called FLT3.

DA: 88 PA: 65 MOZ Rank: 77

Quizartinib, an FLT3 inhibitor, as monotherapy in patients with
nih.gov

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8152787/

WEBQuizartinib is an oral, highly potent, and selective next-generation FLT3 inhibitor with clinical antileukaemic activity in relapsed or refractory acute myeloid leukaemia. We aimed to assess the efficacy and safety of single-agent quizartinib in patients with relapsed or refractory acute myeloid leukaemia.

DA: 63 PA: 41 MOZ Rank: 36